Berry softball coach Darrell Thomas leads team into North Regional next week while undergoing chemotherapy treatments.

Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG ...

China’s NMPA has approved InnoCare Pharma’s orelabrutinib for use as a first-line treatment for CLL and small lymphocytic ...

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that March ...

Researchers sought to assess the access to CAR-T therapy for patients within community-based and transplant cell therapy networks.

High-dose chemotherapy and HSCT can provide long-term benefits in patients with MCL, a retrospective study suggests.

Q1 2025 Management View CEO Chad Robins highlighted a strong start to the year, with MRD revenue increasing 34% year-over-year, driven by clinical volumes, ASP improvements, and pharma sequencing. The ...

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company ...

China NMPA approves InnoCare Pharma’s orelabrutinib for first-line treatment of patients with CLL/SLL: Beijing Monday, April 28, 2025, 12:00 Hrs [IST] InnoCare Pharma, a leading ...

follicular lymphoma marginal zone lymphoma mantle cell lymphoma anemia that’s caused by myelodysplastic syndrome multiple myeloma Revlimid belongs to a class of drugs called thalidomide analogues.

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.